We are adding shares of 3D Signatures (DXD.V) to the Tailwinds Select Portfolio as of the end of March, 2017 at a share price of $.70 CDN.
3D Signatures is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The assays they perform allow the company to measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity on 13 different cancers and Alzheimer’s disease.The technology is well developed and supported by 22 clinical studies on over 2,000 patients. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.